Physician profile
Robert David Tupper
NPI 1700854130
$3,574.95
in general payments reported to CMS, 2019-2025
23 companies · $825 in 2025
The $825 reported for 2025 was more than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $180 · 2020: $51.82 · 2021: $503 · 2022: $591 · 2023: $779 · 2024: $645 · 2025: $825.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,248.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $1,083.94 | 2020-2024 | Citrefix, Augment Injectable, Viaflow |
| Medtronic, INC. | $537.07 | 2024-2025 | Intellis Adaptivestim, Inceptiv, Venaseal |
| Kerecis Limited | $371.74 | 2023-2025 | Kerecis Surgiclose, Kerecis Omega3 Surgiclose, Kerecis Graftguide |
| Smith+Nephew, INC. | $343.44 | 2019-2025 | Grafix Pl, Pico, Renasys Touch |
| Bioventus LLC | $290.42 | 2022-2025 | Exogen Ultrasound Bone Healing System |
| Horizon Therapeutics Plc | $183.67 | 2023 | Krystexxa |
| Medela LLC | $144.65 | 2021-2022 | |
| Convatec INC. | $118.67 | 2023-2025 | |
| Paratek Pharmaceuticals, INC. | $66.85 | 2021-2025 | Nuzyra |
| Organogenesis INC. | $62.44 | 2019-2025 | Puraply Wound Matrix |
| Lifenet Health | $59.61 | 2023-2025 | Theragenesis Wound Matrix |
| Amgen INC. | $50.64 | 2024 | Krystexxa |
| Nevro Corp. | $38.19 | 2022 | |
| Heron Therapeutics, INC. | $34.20 | 2022 | |
| Merck Sharp & Dohme LLC | $28.32 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Sales INC. | $28.03 | 2019 | |
| Next Science LLC | $27.14 | 2023 | Surgx, Xperience, Blastx |
| Misonix INC | $26.14 | 2019-2020 | |
| Abbvie INC. | $21.51 | 2022 | |
| Innovation Technologies INC | $17.38 | 2025 | Irrisept |
| Fidia Pharma USA INC. | $15.32 | 2022 | |
| Abbott Laboratories | $14.59 | 2023 | Proclaim |
| Allergan, INC. | $10.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Tupper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.